VORICONAZOLE-INDUCED HEPATOTOXICITY CONCISE UP-TO-DATE REVIEW


Ertem O., GÜMÜŞTEKİN M.

JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, vol.6, no.1, pp.325-334, 2022 (ESCI) identifier

  • Publication Type: Article / Review
  • Volume: 6 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.30621/jbachs.1051669
  • Journal Name: JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.325-334
  • Keywords: Voriconazole, Hepatotoxicity, Drug induced liver injury, plasma voriconazole concentration, CYP2C19 genotype, INDUCED LIVER-INJURY, TROUGH CONCENTRATION, EFFICACY, SAFETY, CYP2C19, GENOTYPE, GUIDELINES, EXPERIENCE, EXPOSURE
  • Dokuz Eylül University Affiliated: Yes

Abstract

Voriconazole is a wide spectrum antifungal used primarily for invasive aspergillosis, an invasive mold infection occurs mostly in immunocompromised patients. Hepatotoxicity is the most common voriconazole-related adverse reaction that leads to treatment discontinuation. Even though reported incidence of hepatic adverse reactions during phase 2 and 3 clinical trials were less than 10%, observational studies in post marketing phase revealed much higher incidence reaching up to 69%. Therefore, the burden caused by hepatotoxicity and interruption of antifungal therapy put immunocompromised patients at serious risk.